Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023 : vimarsana.com

– 6 Oral Presentations and 28 Posters Across HDV, HCV, HBV, NASH and PSC Highlight Progress and Gilead’s Leadership in Addressing Unmet Needs for People Affected by Liver Disease... | June 14, 2023

Related Keywords

California , United States , Germany , Foster City , Spain , United Kingdom , Italy , Sweden , Frank Duff , Exchange Commission , Gilead Sciences , European Medicines Agency , Gilead Sciences Inc , Committee For Medicinal Products Human Use , Gilead Sciences In Liver Disease , European Commission , Immigration Removal Centers , Risk Of Development , Nasdaq , Ongoing Research In Liver Fibrosis , Practice Plus Group , World Health Organization , European Association , Senior Vice President , Virology Therapeutic Area Head , Hepatitis Elimination , Scientific Highlight , Immigration Removal , Liver Fibrosis , Nonalcoholic Steatohepatitis , Medicinal Products , Human Use , Marketing Authorization , European Economic Area , Important Safety Information , Safety Information And Indication , Symptomatic Bradycardia When Coadministered , Reduced Therapeutic Effect Due , P Gp Inducers , Strong Inducers , Prescribing Information , Safety Information , Worsening Renal Impairment , Severe Hepatomegaly , During Treatment , Crcl Hepatic Impairment , Private Securities Litigation Reform Act , Quarterly Report ,